PARP阻害剤の薬物療法市場：薬剤、適応症、流通チャネル別-2025-2030年の世界予測

PARP阻害剤の薬物療法市場は、2023年に67億3,000万米ドルと評価され、2024年には73億2,000万米ドルに達すると予想され、CAGR 9.15％で成長し、2030年には124億3,000万米ドルに達すると予測されています。

PARP阻害剤は、標的がん治療において極めて重要な薬剤クラス別であり、基本的にはBRCA変異乳がんや卵巣がんなど、特定の遺伝的背景を持つがんの治療に用いられます。これらの阻害剤は、がん細胞のDNA修復に重要なポリADPリボースポリメラーゼという酵素を阻害し、細胞死を誘導することに焦点を当てています。PARP阻害剤の必要性が急増しているのは、その精密標的化能力によるもので、健康な細胞への付随的損傷を最小限に抑え、遺伝的に影響を受けやすい腫瘍に強力な治療効果をもたらします。PARP阻害剤の用途は婦人科系がんだけでなく、前立腺がん、膵臓がん、肺がんなどにも広がりつつあり、最終用途が拡大しています。市場成長の主な要因としては、遺伝子検査に対する認識と導入の増加、個別化医療の発展、臨床試験中のPARP阻害剤の充実したパイプラインなどが挙げられます。さらに、がんの有病率の増加や効果的な治療法に対する緊急の需要も強い刺激となっています。しかし、市場は高い治療費、複雑な薬剤開発スケジュール、耐性機序の出現といった制約に悩まされており、これらは成長への大きな課題となっています。治療機会は、併用療法の調査、治療期間の最適化、奏効予測可能性を高める新規バイオマーカーの探索にあります。バイオテクノロジー企業と学術機関の共同研究は、ブレークスルーを推進する上で極めて重要です。市場力学は、戦略的買収や提携が増加する可能性のある統合段階を示唆しています。技術革新の重点分野としては、薬剤のバイオアベイラビリティを向上させるための新規ドラッグデリバリー・メカニズムの開発や、耐性を克服する次世代阻害剤の探索などが挙げられます。こうした市場のニュアンスを理解し、新たな動向に戦略的イニシアチブを合わせることで、企業は競争優位に立つことができます。急速な技術革新と高い競合を特徴とするPARP阻害剤市場の性質上、規制状況を乗り切り、科学の進歩を活用するための機敏な戦略が必要となります。

市場力学：急速に進化するPARP阻害剤の薬物療法市場の主要市場インサイトを公開

PARP阻害剤の薬物療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんの有病率の増加
  • 世界の臨床試験数の増加
  • PARP医薬品の政府承認の増加
• 市場抑制要因
  • 治療費の高騰
• 市場機会
  • 新たな薬物療法を導入するための継続的な研究開発プロジェクト
  • がん治療強化のための政府プログラム
• 市場の課題
  • 薬物療法の副作用に関する懸念

ポーターのファイブフォース：PARP阻害剤の薬物療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：PARP阻害剤の薬物療法市場における外部からの影響の把握

外部マクロ環境要因は、PARP阻害剤の薬物療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析PARP阻害剤の薬物療法市場における競合情勢の把握

PARP阻害剤の薬物療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスPARP阻害剤の薬物療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、PARP阻害剤の薬物療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨PARP阻害剤の薬物療法市場における成功への道筋を描く

PARP阻害剤の薬物療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品上市、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの罹患率の増加
    • 世界中で臨床試験が増加
    • PARP薬の政府承認の増加
  • 抑制要因
    • 治療費が高い
  • 機会
    • 新しい薬物療法を導入するための進行中の研究開発プロジェクト
    • がん治療療法を強化するための政府プログラム
  • 課題
    • 薬物療法の副作用に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 PARP阻害剤の薬物療法市場薬物別

• ニラパリブ
• オラパリブ
• ルカパリブ
• タラゾパリブ

第7章 PARP阻害剤の薬物療法市場適応症別

• 乳がん
• 卵巣がん
• 膵臓がん
• 前立腺がん

第8章 PARP阻害剤の薬物療法市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのPARP阻害剤の薬物療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のPARP阻害剤の薬物療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのPARP阻害剤の薬物療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Artios Pharma Limited
• AstraZeneca PLC
• BeiGene, Inc.
• Bristol-Myers Squibb Company
• Clovis Oncology
• GlaxoSmithKline PLC
• IMPACT Therapeutics
• Jeil Pharmaceuticals Co. Ltd.
• Jiangsu Hengrui Pharmaceuticals Company Ltd.
• Johnson & Johnson Services, Inc.
• Karyopharm Therapeutics
• Merck & Co., Inc.
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Repare Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PARP INHIBITORS DRUG THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 32. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 104. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 116. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 119. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The PARP Inhibitors Drug Therapy Market was valued at USD 6.73 billion in 2023, expected to reach USD 7.32 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 12.43 billion by 2030.

PARP inhibitors are a class of drugs pivotal to targeted cancer therapy, fundamentally employed in treating cancers with specific genetic contexts, such as BRCA-mutated breast and ovarian cancers. These inhibitors focus on blocking the enzyme poly ADP-ribose polymerase, crucial for DNA repair in cancer cells, thus inducing cell death. The burgeoning necessity for PARP inhibitors stems from their precision-targeting capability, which minimizes collateral damage to healthy cells and delivers a potent therapeutic effect in genetically susceptible tumors. Their application is extending beyond gynecological cancers to potentially include prostate, pancreatic, and lung cancers, broadening their end-use scope. Key market growth influencers include increased awareness and adoption of genetic testing, developments in personalized medicine, and a robust pipeline of PARP inhibitors under clinical trials. Additionally, the growing prevalence of cancer and the urgent demand for effective therapies serve as strong stimuli. However, the market grapples with limitations such as high treatment costs, complex drug development timelines, and the emergence of resistance mechanisms, which are substantial challenges to growth. Opportunities lie in advancing research for combination therapies, optimizing treatment durations, and exploring novel biomarkers to enhance response predictability. The interplay of collaborations between biotech firms and academic institutions can be pivotal in driving breakthroughs. Market dynamics suggest a consolidation phase with a potential upswing in strategic acquisitions and partnerships. Focus areas for innovation include formulating novel delivery mechanisms to improve drug bioavailability and exploring next-generation inhibitors overcoming resistance. Understanding these market nuances and aligning strategic initiatives with emerging trends can offer firms a competitive advantage. The nature of the PARP inhibitors market, characterized by rapid innovation and high competition, necessitates agile strategies to maneuver through regulatory landscapes and capitalize on scientific advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PARP Inhibitors Drug Therapy Market

The PARP Inhibitors Drug Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancers
  • Growing numbers of clinical trials worldwide
  • Elevation in government approvals for PARP drugs
• Market Restraints
  • High cost of treatment
• Market Opportunities
  • Ongoing research and development projects to introduce novel drug therapies
  • Governmental programs to enhance the cancer treatment therapies
• Market Challenges
  • Concerns associated with side effects of drug therapy

Porter's Five Forces: A Strategic Tool for Navigating the PARP Inhibitors Drug Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PARP Inhibitors Drug Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PARP Inhibitors Drug Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PARP Inhibitors Drug Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PARP Inhibitors Drug Therapy Market

A detailed market share analysis in the PARP Inhibitors Drug Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PARP Inhibitors Drug Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PARP Inhibitors Drug Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PARP Inhibitors Drug Therapy Market

A strategic analysis of the PARP Inhibitors Drug Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PARP Inhibitors Drug Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Artios Pharma Limited, AstraZeneca PLC, BeiGene, Inc., Bristol-Myers Squibb Company, Clovis Oncology, GlaxoSmithKline PLC, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Company Ltd., Johnson & Johnson Services, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Repare Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the PARP Inhibitors Drug Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Niraparib, Olaparib, Rucaparib, and Talazoparib.
• Based on Indication, market is studied across Breast Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancers
    • 5.1.1.2. Growing numbers of clinical trials worldwide
    • 5.1.1.3. Elevation in government approvals for PARP drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development projects to introduce novel drug therapies
    • 5.1.3.2. Governmental programs to enhance the cancer treatment therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with side effects of drug therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. PARP Inhibitors Drug Therapy Market, by Drug

• 6.1. Introduction
• 6.2. Niraparib
• 6.3. Olaparib
• 6.4. Rucaparib
• 6.5. Talazoparib

7. PARP Inhibitors Drug Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Ovarian Cancer
• 7.4. Pancreatic Cancer
• 7.5. Prostate Cancer

8. PARP Inhibitors Drug Therapy Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas PARP Inhibitors Drug Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific PARP Inhibitors Drug Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Artios Pharma Limited
• 3. AstraZeneca PLC
• 4. BeiGene, Inc.
• 5. Bristol-Myers Squibb Company
• 6. Clovis Oncology
• 7. GlaxoSmithKline PLC
• 8. IMPACT Therapeutics
• 9. Jeil Pharmaceuticals Co. Ltd.
• 10. Jiangsu Hengrui Pharmaceuticals Company Ltd.
• 11. Johnson & Johnson Services, Inc.
• 12. Karyopharm Therapeutics
• 13. Merck & Co., Inc.
• 14. Ono Pharmaceutical Co., Ltd.
• 15. Pfizer Inc.
• 16. Repare Therapeutics, Inc.